Merck's Keytruda Gets FDA Priority Review for Head/Neck Cancer

  • In Science
  • 2019-02-12 14:12:02Z
  • By Zacks Equity Research

Merck & Co., Inc. MRK announced that the FDA has granted a priority review to yet another supplemental biologics license application (sBLA) for its PD-L1 inhibitor, Keytruda. With the latest sBLA filing, Merck is looking to get Keytruda approved for the first-line treatment of patients suffering recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), both as a monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy.

With the FDA granting a priority review to the sBLA, a decision is expected on Jun 10, 2019. The approval will help Merck gain access to a broader patient population and boost sales for its blockbuster drug.

The sBLA was based on data from the phase III KEYNOTE-048 study wherein Keytruda as a monotherapy and also combined with chemotherapy demonstrated a significant improvement in overall survival (OS) as compared to the standard of care in the given patients, whose tumors expressed PD-L1 with CPS(combined proportion score)≥20 and CPS≥1.

Shares of Merck have surged 39.8% in the past year, outperforming the industry's increase of 7.1%.

Keytruda is already approved for many types of cancers and treatment settings including lung cancer, melanoma, head and neck cancer, classical Hodgkin's lymphoma and bladder cancer.

In a very short span of time, Keytruda has become the largest product in Merck's portfolio. The drug generated sales of $7.17 billion in 2018, reflecting a massive 88% surge year over year. Sales were driven by the launch of new indications globally. Keytruda sales are particularly gaining from a strong momentum in first-line lung cancer indication as it is the only anti-PD-1 medicine approved in first-line setting.

The Keytruda development program is also progressing well and the drug is being studied for more than 30 types of cancer in above 900 studies including 400 plus combination programs. Merck is collaborating with several companies, namely Amgen AMGN, Incyte INCY, Glaxo GSK and Pfizer, separately, for the evaluation of Keytruda in combination with other regimes.

Zacks Rank

Merck currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Zacks' Best Stock-Picking Strategy

It's hard to believe, even for us at Zacks. But from 2000-2018, while the market gained +4.8% per year, our top stock-picking strategy averaged +54.3% per year.

How has that screen done lately? From 2017-2018, it sextupled the market's +15.8% gain with a soaring +98.3% return.

Free - See the Stocks It Turned Up for Today >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

GlaxoSmithKline plc (GSK) : Free Stock Analysis Report

Amgen Inc. (AMGN) : Free Stock Analysis Report

Incyte Corporation (INCY) : Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

More Related News

What the FDA Needs You to Know About Alzheimer's "Cures"
What the FDA Needs You to Know About Alzheimer's "Cures"

If a supplement sounds too good to be true, it probably is-the FDA is cracking down on the companies peddling false promises.

Merck to further study Keytruda in prostate cancer after early success
Merck to further study Keytruda in prostate cancer after early success

(Reuters) - Merck & Co Inc said on Thursday it was launching three late-stage studies for its cancer immunotherapy Keytruda as a combination treatment for prostate cancer after the drug showed anti-tumor activity in an early-stage trial. The interim findings of the trial testing Keytruda in combination with other cancer drugs such as Lynpraza, which it jointly develops and sells with AstraZeneca, and chemotherapy docetaxel showed anti-tumor activity, Merck said. "These promising data .. ...

E. coli-tainted romaine lettuce came from California farms, FDA report says
E. coli-tainted romaine lettuce came from California farms, FDA report says

Investigators said a number of California farms may have produced the tainted romaine lettuce that caused an E. coli outbreak sickening 62 people.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply


Top News: Science

Hit "Like"
Don't miss any important news
Thanks, you don't need to show me this anymore.